Science and Technology
publicado em 23/12/2009 às 20h15:00
   Dê o seu voto:

Product trabectedin is recommended as the new system against cancer

Research on new drug showed an increase in life expectancy of patients with soft tissue sarcoma in the United Kingdom

font size

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.

Foto: Divulgação/Eurofins
Production of laboratory medicine
  « Previous
next »  
Production of laboratory medicine

Patients with a rare form of cancer called advanced soft tissue sarcoma could now benefit from a new drug called trabectedin, after the National Institute for Health and Clinical Excellence (NICE) approved the drug for NHS use.

The disease develops in the body's soft supportive tissue - such as fat, muscle and blood vessels - and affects around 2,000 people a year in the UK.

Trabectedin works by damaging the DNA in cancer cells, preventing them from growing and spreading to other parts of the body.

Research suggests that the drug may extend life by at least three months more than other NHS treatments and that it may therefore be beneficial for some of the 500 to 600 people in England and Wales with advanced soft tissue sarcoma.

In its preliminary draft guidance, NICE had argued that trabectedin would not be a cost-effective use of NHS resources, but it has since changed its mind thanks to a cost-sharing scheme agreed with manufacturer PharmaMar.

The drug has now been recommended in the institute's final draft guidance, with the NHS paying for each patient's first five treatment cycles and PharmaMar funding any cycles beyond this.

Under the latest guidance, the drug is recommended as a treatment for people with advanced soft tissue sarcoma who have previously failed to respond to treatment with anthracyclines and ifosfamide, or who are unable to tolerate those treatments.

Dr Carole Longson, director at the NICE Health Technology Evaluation Centre, said: "We are delighted the Independent Appraisal Committee has been able to recommend trabectedin in its draft guidance. It has certainly not been an easy decision to make; soft tissue sarcoma is a rare cancer and the evidence was limited.

"However, treatment options for this type of cancer are limited and in the last 20 years there have been no major developments to treat the advanced stages of this disease. Being able to recommend trabectedin for use on the NHS represents a step forward in the care of this group of patients who may have very few treatment options left.".

   Palavras-chave:   Soft tissue sarcoma    Trabectedin    Cancer    NHS    NICE    Anthracyclines    Ifosfamide    Carole Longson   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Product trabectedin is recommended as the new system against cancer
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Product trabectedin is recommended as the new system against cancer

Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
soft tissue sarcoma    trabectedin    cancer    NHS    NICE    anthracyclines    ifosfamide    Carole Longson   
Leave your comment
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story:
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaú
Get the newsletter of the portal  iSaú
Recommend the portal iSaú
News from  iSaú in your blog or website.
Get news on the subject of your interest.
© 2000-2011 Todos os direitos reservados.